Histological Study to Assess Safety and Efficacy of the TempSure Firm for Non-Invasive Lipolysis

Cynosure

Status: Completed

Conditions: Non-invasive Lipolysis

Treatments: Device: TempSure Firm

Study type: Interventional

Funder types: Industry

Identifiers

NCT04878172

7027-MCPL-2021

Details and patient eligibility

About

This is a prospective, open-labeled, non-randomized, multi-center clinical study to collect safety and efficacy data on the TempSure Firm. The intended use of the TempSure device is to use the Firm handpieces for non-invasive lipolysis.

Full description

Up to 12 subjects will be enrolled at up to 3 study centers. Subjects will attend a screening/pretreatment visit which may be performed on the same day as the treatment visit. Subjects may receive 1 treatment on the abdomen with the TempSure firm. Subjects will undergo abdominoplasty surgery at one of 4 predetermined timepoint after an abdomen treatment: day 0 (within 24 hours after treatment), 10 days (+/- 3 days), 20 days (+/- 3 days), or 30 days (+/- 7 days). This will be determined by the availability of the subject and/or an as needed basis and this will be decided by the Investigator and the Sponsor.

Enrollment: 9 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female between 18 - 55 years old.
• Willing to receive treatments with the TempSure® device and willing to have biopsies taken from a control site and the treatment area (biopsies are collected after the abdominal tissue flap is removed during abdominoplasty surgery)
• Understand and accept obligation not to receive any other procedures on the treatment and control areas throughout the length of the study.
• Understand and accept the obligation and able to be present for all study visits
• Willing to comply with all requirements of the study and able to provide informed consent.

Exclusion criteria

Pregnant or of childbearing potential and not using medically effective birth control, or has been pregnant in the last 3 months, currently breast feeding or planning to become pregnant prior to the end of the study.

• Currently enrolled in an investigational drug or device trial, or has received an investigational drug or investigational device treatment(s) in the area to be treated (or designated control area) 6 months prior to entering this study (or at the discretion of the Investigator) .
• Cuts, wounds, or infected skin on the area to be treated or designated control area
• On local, oral, or systemic anesthetic agents.
• Condition(s) or circumstance(s) that, in the investigators opinion, may put the subject at significant risk, may confound study results or may interfere significantly with subject participation.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

9 participants in 4 patient groups

TempSure Firm Day 0 Biopsy Group

Experimental group

Description:

Subjects will undergo abdominal surgery after an abdominal treatment with TempSure Firm at day 0 (within 24 hours after treatment).

Treatment:

Device: TempSure Firm

TempSure Firm Day 10 Biopsy Group

Experimental group

Description:

Subjects will undergo abdominal surgery after an abdominal treatment with TempSure Firm at day 10 (+/- 3 days) after treatment.

Treatment:

Device: TempSure Firm

TempSure Firm Day 20 Biopsy Group

Experimental group

Description:

Subjects will undergo abdominal surgery after an abdominal treatment with TempSure Firm at day 20 (+/- 3 days) after treatment.

Treatment:

Device: TempSure Firm

TempSure Firm Day 30 Biopsy Group

Experimental group

Description:

Subjects will undergo abdominal surgery after an abdominal treatment with TempSure Firm at day 30 (+/- 7 days) after treatment.

Treatment:

Device: TempSure Firm